CD274 and non-small cell lung carcinoma: If immune checkpoint inhibitors targeting PD-1 and PD-L1 have radically changed the NSCLC treatment landscape and its prognosis, only twenty percent of patients will finally really benefit from it, and identifying those patients seems necessary in order to prevent potential toxicity.